Restricted accessReview articleFirst published online 2026-3
Association between varicella-zoster virus and Alzheimer's disease: A systematic review and meta-analysis of comprehensive evidence from infection,treatment to prevention
The association between varicella-zoster virus (VZV) infection and Alzheimer's disease (AD) risk has shown inconsistent results. Given difficulties in early diagnosis and limited therapeutic options for AD, identifying modifiable risk factors is significant for prevention.
Objective
To systematically evaluate the impact of VZV infection on AD risk and explore protective effects of antiviral treatment and vaccination.
Methods
We searched PubMed and Web of Science databases up to April 2025. The Newcastle-Ottawa Scale assessed study quality. Random-effects models were used for meta-analysis using risk ratios (RR) as the primary effect measure, with sensitivity and subgroup analyses conducted.
Results
Twenty-one studies were included. Meta-analysis showed: (1) herpes zoster patients had significantly higher AD risk (RR = 1.12, 95% CI: 1.01–1.24, p = 0.04); (2) patients receiving antiviral treatment had lower AD risk (RR = 0.55, 95% CI: 0.37–0.82, p = 0.003); (3) vaccinated individuals had lower AD risk (RR = 0.72, 95% CI: 0.68–0.78, p < 0.0001). The strongest association occurred in the >70 years age group, demonstrating age as an important effect modifier.
Conclusions
This meta-analysis provides systematic evidence supporting that VZV infection increases AD risk while confirming protective effects of antiviral treatment and vaccination. These findings support including herpes zoster vaccination in preventive healthcare for elderly populations.
SallowaySSperlingRBrashearHR. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med2014; 370: 322–333.
4.
DhillonS. Aducanumab: first approval. Drugs2021; 81: 1437–1443.
5.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet2020; 396: 413–446.
6.
WuXYangHHeS, et al.Adult vaccination as a protective factor for dementia: a meta-analysis and systematic review of population-based observational studies. Front Immunol2022; 13: 872542.
7.
UkraintsevaSYashkinAPAkushevichI, et al.Associations of infections and vaccines with Alzheimer's disease point to a role of compromised immunity rather than specific pathogen in AD. Exp Gerontol2024; 190: 112411.
8.
HonjoKvan ReekumRVerhoeffNP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?Alzheimers Dement2009; 5: 348–360.
9.
RubinKGlazerS. The pertussis hypothesis: bordetella pertussis colonization in the pathogenesis of Alzheimer's disease. Immunobiology2017; 222: 228–240.
10.
LรถvheimHGilthorpeJJohanssonA, et al.Herpes simplex infection and the risk of Alzheimer's disease: a nested case-control study. Alzheimers Dement2015; 11: 587–592.
11.
LandryRLEmbersME. Does dementia have a microbial cause?NeuroSci2022; 3: 262–283.
12.
Warren-GashCForbesHJWilliamsonE, et al.Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep2019; 9: 4743.
13.
BaeSYunSCKimMC, et al.Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study. Eur Arch Psychiatry Clin Neurosci2021; 271: 987–997.
14.
YehT-SCurhanGCYawnBP, et al.Herpes zoster and long-term risk of subjective cognitive decline. Alzheimers Res Ther2024; 16: 80.
15.
ZhuLFHuCCMeiY, et al.Effect of varicella-zoster virus infection and antiviral treatment on the risk for dementia: a meta-analysis of observational studies. Brain Behav2024; 14: e3407.
16.
LiHLiuCCZhengH, et al.Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl Neurodegener2018; 7: 34.
17.
EimerWAVijaya KumarDKNavalpur ShanmugamNK, et al.Alzheimer's disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron2018; 99: 56–63.e3.
18.
BubakANComoCNHassellJEJr, et al.Targeted RNA sequencing of VZV-infected brain vascular adventitial fibroblasts indicates that amyloid may be involved in VZV vasculopathy. Neurol Neuroimmunol Neuroinflamm2021; 9: e1103.
19.
ReadheadBHaure-MirandeJVFunkCC, et al.Multiscale analysis of independent Alzheimer's cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron2018; 99: 64–82.e67.
20.
TorrentMPulidoDNoguรฉsMV, et al.Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog2012; 8: e1003005.
21.
WangJPKurt-JonesEAShinOS, et al.Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via toll-like receptor 2. J Virol2005; 79: 12658–12666.
22.
TanZSBeiserASVasanRS, et al.Inflammatory markers and the risk of Alzheimer disease: the framingham study. Neurology2007; 68: 1902–1908.
23.
MonsonegoANemirovskyAHarpazI. CD4T Cells in immunity and immunotherapy of Alzheimer's disease. Immunology2013; 139: 438–446.
24.
SullivanNLEberhardtCSWielandA, et al.Understanding the immunology of the zostavax shingles vaccine. Curr Opin Immunol2019; 59: 25–30.
25.
JhaVJanoffEN. Complementary role of CD4+ T cells in response to pneumococcal polysaccharide vaccines in humans. Vaccines (Basel)2019; 7: 18.
26.
ChenVCWuSIHuangKY, et al.Herpes zoster and dementia: a nationwide population-based cohort study. J Clin Psychiatry2018; 79: 16m11312.
27.
Lopatko LindmanKHemmingssonESWeidungB, et al.Herpesvirus infections, antiviral treatment, and the risk of dementia-a registry-based cohort study in Sweden. Alzheimers Dement (N Y)2021; 7: e12119.
28.
MaplePACHosseiniAA. Human alpha herpesviruses infections (HSV1, HSV2, and VZV), Alzheimer's disease, and the potential benefits of targeted treatment or vaccination-a virological perspective. Vaccines (Basel)2025; 13: 72.
29.
TzengNSChungCHLinFH, et al.Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections-a nationwide, population-based cohort study in Taiwan. Neurotherapeutics2018; 15: 417–429.
30.
SchnierCJanbekJWilliamsL, et al.Antiherpetic medication and incident dementia: observational cohort studies in four countries. Eur J Neurol2021; 28: 1840–1848.
31.
Warren-GashCWilliamsonEShiekhSI, et al.No evidence that herpes zoster is associated with increased risk of dementia diagnosis. Ann Clin Transl Neurol2022; 9: 363–374.
32.
ShinEChiSAChungT-Y, et al.The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study. Alzheimers Res Ther2024; 16: 57.
33.
ChoiHGParkBJLimJS, et al.Herpes zoster does not increase the risk of neurodegenerative dementia: a case-control study. Am J Alzheimers Dis Other Demen2021; 36: 15333175211006504.
34.
BlandiLBertuccioPSignorelliC, et al.Herpes zoster as risk factor for dementia: a matched cohort study over 20 years in a 10-million population in Italy. J Prev Alzheimers Dis2025; 12: 100167.
35.
TsaiM-CChengW-LSheuJ-J, et al.Increased risk of dementia following herpes zoster ophthalmicus. PloS One2017; 12: e0188490.
36.
SchmidtSAJVeresKSørensenHT, et al.Incident herpes zoster and risk of dementia: a population-based Danish cohort study. Neurology2022; 99: e660–e668.
37.
ShimYParkMKimJ. Increased incidence of dementia following herpesvirus infection in the Korean population. Medicine (Baltimore)2022; 101: e31116.
38.
LophatananonAMekliKCantR, et al.Shingles, Zostavax vaccination and risk of developing dementia: a nested case-control study-results from the UK Biobank cohort. BMJ Open2021; 11: e045871.
39.
LinardMBezinJHucteauE, et al.Antiherpetic drugs: a potential way to prevent Alzheimer's disease?Alzheimers Res Ther2022; 14: 3.
40.
TangERayIArnoldBF, et al.Recombinant zoster vaccine and the risk of dementia. Vaccine2025; 46: 126673.
41.
SchnierCJanbekJLatheR, et al.Reduced dementia incidence after varicella zoster vaccination in Wales 2013–2020. Alzheimers Dement (N Y)2022; 8: e12293.
42.
ScherrerJFSalasJWiemkenTL, et al.Impact of herpes zoster vaccination on incident dementia: a retrospective study in two patient cohorts. PLoS One2021; 16: e0257405.
43.
HarrisKLingYBukhbinderAS, et al.The impact of routine vaccinations on Alzheimer’s disease risk in persons 65 years and older: a claims-based cohort study using propensity score matching. J Alzheimers Dis2023; 95: 703–718.
44.
LehrerSRheinsteinPH. Herpes zoster vaccination reduces risk of dementia. In Vivo2021; 35: 3271–3275.
45.
WiemkenTLSalasJMorleyJE, et al.Comparison of rates of dementia among older adult recipients of two, one, or no vaccinations. J Am Geriatr Soc2022; 70: 1157–1168.
46.
ShahSDahalKThapaS, et al.Herpes zoster vaccination and the risk of dementia: a systematic review and meta-analysis. Brain Behav2024; 14: e3415.
47.
EytingMXieMMichalikF, et al.A natural experiment on the effect of herpes zoster vaccination on dementia. Nature2025; 641: 438–446.
48.
ElhalagRHMotaweaKRTalatNE, et al.Herpes zoster virus infection and the risk of developing dementia: a systematic review and meta-analysis. Medicine (Baltimore)2023; 102: e34503.
49.
LinH-SLinY-STsaiY-S, et al.Association of herpes zoster with dementia: a systematic review and meta-analysis with GRADE assessment. Dermatol Sin2024; 42: 128–135.
50.
YinYDengJLiuJ. The association between herpes zoster vaccination and the decreased risk of dementia: a systematic review and meta-analysis of cohort studies. J Alzheimers Dis2025; 106: 1232–1241.
51.
HarrisTNairJFediurekJ, et al.Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15. Vaccine2017; 35: 2600–2604.
52.
SochockaMZwolińskaKLeszekJ. The infectious etiology of Alzheimer's disease. Curr Neuropharmacol2017; 15: 996–1009.
53.
ItzhakiRFLatheR. Herpes viruses and senile dementia: first population evidence for a causal link. J Alzheimers Dis2018; 64: 363–366.
54.
MahleyRWRallSCJr. Apolipoprotein E: far more than a lipid transport protein. Ann Rev Genom Hum Genet2000; 1: 507–537.
55.
SasakiMKodamaCHidakaS, et al.Prevalence of four subtypes of mild cognitive impairment and APOE in a Japanese community. Int J Geriatr Psychiatry2009; 24: 1119–1126.
56.
IrieFMasakiKHPetrovitchH, et al.Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the honolulu-Asia aging study. Arch Gen Psychiatry2008; 65: 906–912.
57.
BharathSPurushottamMMukherjeeO, et al.Apolipoprotein E polymorphism and dementia: a hospital-based study from southern India. Dement Geriatr Cogn Disord2010; 30: 455–460.
58.
StrandbergTEPitkalaKEerolaJ, et al.Interaction of herpesviridae, APOE gene, and education in cognitive impairment. Neurobiol Aging2005; 26: 1001–1004.
59.
WozniakMAShipleySJDobsonCB, et al.Does apolipoprotein E determine outcome of infection by varicella zoster virus and by Epstein Barr virus?Eur J Hum Genet2007; 15: 672–678.
60.
KleinSLMarriottIFishEN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg2015; 109: 9–15.
61.
MarkleJGFishEN. SeXX matters in immunity. Trends Immunol2014; 35: 97–104.
62.
GiridharanVVMasudFPetronilhoF, et al.Infection-induced systemic inflammation is a potential driver of Alzheimer's disease progression. Front Aging Neurosci2019; 11: 22.
63.
BubakANComoCNCoughlanCM, et al.Varicella-zoster virus infection of primary human spinal astrocytes produces intracellular amylin, amyloid-β, and an amyloidogenic extracellular environment. J Infect Dis2020; 221: 1088–1097.
64.
DagnewAFKleinNPHerveC, et al.The adjuvanted recombinant zoster vaccine in adults aged >/=65 years previously vaccinated with a live-attenuated herpes zoster vaccine. J Infect Dis2021; 224: 1139–1146.
65.
DoolingKLGuoAPatelM, et al.Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep2018; 67: 103–108.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
